Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials,The Journal of Infectious Diseases

当前位置： X-MOL 学术 › J. Infect. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
The Journal of Infectious Diseases ( IF 5.0 ) Pub Date : 2024-09-03 , DOI: 10.1093/infdis/jiae400
Holly Janes ₁ , Leigh H Fisher ₁ , Jia Jin Kee ₁ , Lalitha Parameswaran ₂ , Paul A Goepfert ₃ , Ann R Falsey ₄ , James Ludwig ₁ , Craig A Magaret ₁ , Peter B Gilbert ₁ , James G Kublin ₁ , Nadine Rouphael ₅ , Magdalena E Sobieszczyk ₆ , Hana M El Sahly ₇ , Lindsey R Baden ₈ , Beatriz Grinsztejn ₉ , Stephen R Walsh ₈ , Glenda E Gray ₁₀ , Karen L Kotloff ₁₁ , Cynthia L Gay ₁₂ , Alexander L Greninger ₁₃ , Milagritos D Tapia ₁₁ , E Adrianne Hammershaimb ₁₁ , Frances H Priddy ₁₄ , Justin A Green ₁₅ , Frank Struyf ₁₆ , Lisa Dunkle ₁₇ , Kathleen M Neuzil ₁₈ , Lawrence Corey ₁ , Yunda Huang ₁

Affiliation

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
New York University Langone Vaccine Center, New York University Grossman School of Medicine, New York, New York, USA.
Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Infectious Disease Division, University of Rochester, Rochester, New York, USA.
Hope Clinic, Emory University, Atlanta, Georgia, USA.
Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
South African Medical Research Council, Cape Town, South Africa.
Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Department of Medicine, Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, USA.
Moderna, Inc, Cambridge, Massachusetts, USA.
Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, United Kingdom.
Janssen Research and Development, Beerse, Belgium.
Novavax, Inc, Gaithersburg, Maryland, USA.
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38–4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44–2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, −.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, −.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.

中文翻译：

4 项 3 期试验中 SARS-CoV-2 病毒载量与 COVID-19 疫苗接种之间的关联

2019 冠状病毒病（COVID-19）疫苗可降低重症和死亡率，并可能减少传播，通过严重急性呼吸系统综合症冠状病毒 2 （SARS-CoV-2）病毒载量（VL）来衡量。在 2020 年 7 月至 2021 年 7 月的 4 项 3 期随机、安慰剂对照疫苗试验中评估 COVID-19 诊断时 VL 与 VL 的关联，NVX-CoV2373 和 mRNA-1273 的 VL 减少为 2.78 log10 拷贝/mL（95% CI，1.44-2.80;n = 594 安慰剂，36 疫苗），分别。AZD1222组（0.59 log10 拷贝/mL;95% CI，-.19 至 1.36;n = 90 安慰剂，78 种疫苗）或 Ad26.COV2.S（0.23 log10 拷贝/mL;95% CI，-.01 至 .47;n = 916 安慰剂，424 种疫苗）的相关性不显著。因此，当祖先 SARS-CoV-2 占主导地位时，疫苗可能会减少传播。临床试验注册。NCT04470427、NCT04505722、NCT04516746 NCT04611802。

更新日期：2024-09-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文